2003 Archive

December 17, 2003
Lp-PLA2 Targeted for Therapeutic Intervention
diaDexus offers FDA-cleared test to measure Lp-PLA2

November 10, 2003
Lp-PLA2 As An Independent Predictor Of Coronary Events In Men
Professor Wolfgang Koenig, MD Presents MONICA Study Data at 2003 AHA Scientific Session

July 18, 2003
diaDexus Receives FDA Marketing Clearance for PLAC® Test
The PLAC® Test Identifies Patients at Risk for Coronary Heart Disease

April 2, 2003
Late-Breaking Clinical News Presented at the American College of Cardiology
New Data Show Lp-PLA2 And CRP Associated With Incidence Of Coronary Heart Disease

March 28, 2003
diaDexus Will Supply Analyte Specific Reagents for Use in a Test to Measure Lp-PLA2 in Blood

March 5, 2003
diaDexus Announces Submission of 510 (k) Pre-Market Notification

February 12, 2003
diaDexus Exclusively Licenses Rights Related to Testisin, a Novel Serine Protease Cancer Target, from Queensland Institute of Medical Research

January 29, 2003
Medarex and diaDexus Form Collaboration for the Development of Fully Human Antibody Therapeutics